SCHEMBL10326754

SCHEMBL10326754

CN1C(=O)[C@@H](Cc2c[nH]c3ccccc23)NC1(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.59
IDO1 P14902 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
TP53 P04637 1/20 0.59
GLA P06280 1/20 0.59
CYP3A4 P08684 1/20 0.59
THRB P10828 1/20 0.59
RIPK1 Q13546 1/20 0.59
HSD17B10 Q99714 1/20 0.59
KMT2A Q03164 6/20 0.57
POLB P06746 2/20 0.57
KDM4E B2RXH2 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
MEN1 O00255 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
LMNA P02545 2/20 0.50
PKM P14618 1/20 0.50
TNF P01375 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10327106 1.00 MAPT (0.59) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL10326471 1.00 MAPT (0.59) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL876699 0.77 RIPK1 (0.79) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL29764703 0.77 RIPK1 (0.79) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL837717 0.77 RIPK1 (0.79) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL877381 0.77 RIPK1 (0.79) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL7601366 0.77 RIPK1 (0.73) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL14218300 0.76 MAPT (0.62) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL23266703 0.75 MAPT (0.60) MAPTIDO1SMN1; SMN2TP53GLA
SCHEMBL14982035 0.75 RIPK1 (0.75) MAPTIDO1SMN1; SMN2TP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 MAPT 2035/4885IDO1 1442/4885SMN1; SMN2 3083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.